AstraZeneca's Recentin Plus FOLFOX4 to Earn 10 Percent Patient Share in the Treatment of Colorectal Cancer By 2016
Posted on: Wednesday, 2 April 2008, 09:01 CDT
WALTHAM, Mass., April 2, 2008 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, forecasts that AstraZeneca's Recentin plus FOLFOX4 will earn 10 percent patient share first-line stage IV colorectal cancer market in the U.S. by 2016. Additionally, oncologists indicate that they would prescribe this combination to 33 percent of their patients in the first-line setting for stage IV colorectal cancer.
"Although oncologists interviewed are eager to prescribe Recentin plus FOLFOX4, competition from the established Avastin will limit patient share," said Marcus Hoyle, analyst at Decision Resources. "According to oncologists interviewed, physicians are gaining familiarity and comfort with prescribing Avastin in the first-line setting, limiting the uptake of emerging agents."
According to the new report entitled Colorectal Cancer (Stage IV): Therapies Must Increase Overall Survival over IFL plus Bevacizumab to Reach Blockbuster Status, physicians indicate that the most promising emerging therapies for the treatment of colorectal cancer will not match the current gold standard, CAPOX plus bevacizumab. CAPOX plus bevacizumab consists of Roche's Xeloda, Sanofi-Aventis's Eloxatin/Eloxatine, Yakult-Honsha's Elplat plus Roche/Genentech/Chugai's Avastin. All three emerging therapies- AstraZeneca's Recentin (plus FOLFOX4), Bristol-Myers Squibb/ImClone Systems/Merck KGaA's Erbitux (plus FOLFIRI), and Pfizer's Sutent (plus FOLFIRI)-consist of a targeted agent combined with an existing chemotherapy regimen. Experts interviewed believe that all three emerging therapies will demonstrate efficacy similar to that of currently available bevacizumab- containing regimens. However, the safety and tolerability attributes of CAPOX plus bevacizumab differentiate the regimen from all other current and emerging therapies and ensure its gold-standard status through 2016.
About the Report
Colorectal Cancer (Stage IV): Therapies Must Increase Overall Survival over IFL plus Bevacizumab to Reach Blockbuster Status is a DecisionBase 2008 report from Decision Resources. DecisionBase 2008 combines market forecasts with clinical and commercial end points to assess market share projections in 35 indications. These outputs are driven by quantitative and qualitative primary research. DecisionBase 2008 provides detailed market share, patient share, and price-per-day projections for emerging drugs in development. The market share projections are based on prescriber surveys that compare physicians' expectations of a potential target product profile with an emerging product profile of the leading drugs in development.
The report can be purchased by contacting Decision Resources. Members of the media may request an interview with an analyst.
About Decision Resources
Decision Resources, Inc. (http://www.decisionresources.com/) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders. For more information, contact: Elizabeth Marshall Decision Resources, Inc. 781-296-2563 emarshall@dresources.com
Decision Resources
CONTACT: Elizabeth Marshall of Decision Resources, Inc.,+1-781-296-2563, emarshall@dresources.com
Web site: http://www.decisionresources.com/
Source: PRNewswire
Related Articles
- Sanofi-Aventis' and Roche/Chugai's Drugs Will Dominate the Indian Colorectal Cancer Drug Market Through 2013
- Chinese Colorectal Cancer Drug Market Will More Than Double by 2012
- Use of Avastin and Erbitux in the Adjuvant Setting and Launches of Emerging Agents Will Drive the Colorectal Cancer Drug Market to $7.8 Billion in 2017
- The Cystic Fibrosis (CF) Market is Poised for Significant Change. Will New Agents Emerge As First-Line Therapies?
- Study Suggests Survival Benefit From Radioactive Microsphere Therapy in Patients With Colorectal Cancer Liver Metastases Who Have Failed Chemotherapy
- Target Product Profiles 2008 Colorectal Cancer Report Qualitatively Predicts the Market Potential of a Drug Fulfilling a Key Unmet Need
- In Spite Of Strong Growth to Date, Sales of Eloxatin for Colorectal Cancer Are Expected To Slow Down Significantly In the Coming Years As Generic Oxaliplatin Begins To Enter the EU Markets
- Colorectal Cancer: Bad NICE News for Avastin and Erbitux
- Third Wave and Genzyme Genetics Announce Preferred Marketing Relationship for Colorectal Cancer Personalized Medicine Test
 |
 |
User Comments (0)
RSS Feeds